Today: 29 June 2026
Browse Category

NASDAQ:FEMY 16 October 2025 - 23 May 2026

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys shares jumped as much as 25% pre-market Nov. 3 after the company won FDA approval to begin the final phase of its FemBloc pivotal trial and secured up to $58 million in new financing. FEMY closed up 8% at $0.69 after hitting $0.79 intraday. FemBloc recently gained CE Mark and approvals in the UK and New Zealand. Q2 sales rose 85% to $0.41 million, with a net loss of $4.59 million.
3 November 2025
·
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys Inc. shares surged 46% intraday on Oct. 16, 2025, closing up 35% at $0.745 amid heavy trading. The rally followed news of regulatory approvals for its FemBloc® birth control system in Europe, UK, and New Zealand, and a major order from a Spanish distributor. The company also announced new partnerships and showcased its fertility treatments at an industry conference. Femasys remains unprofitable but reported 85% year-over-year sales growth in Q2.
17 October 2025
··
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (NASDAQ: FEMY) jumped 46% to $0.80 by mid-day Oct. 16 after announcing its FemaSeed fertility treatment will be showcased at ASRM 2025. The company recently secured European, UK, and New Zealand approvals for its FemBloc birth control device and reported its first European sales and new distribution deals. Q2 revenue rose 85% year-over-year to $0.409 million.
16 October 2025
··

Stock Market Today

  • Screen Australia Launches Private Investment Toolkit to Bridge Gap Between Producers and Investors
    June 28, 2026, 9:42 PM EDT. Screen Australia has unveiled a free, interactive Private Investment Toolkit aimed at educating screen producers and potential investors. The digital platform stresses a 'market-informed mindset,' providing guidance on pitching, risk management, value setting, and timelines. It helps investors understand Australia's screen sector, tailor investment strategies, and align goals, covering profit-driven and philanthropic investment paths. Developed with industry experts, the toolkit seeks to demystify private investment, enhance transparency, and standardize practices to foster stronger partnerships. Grainne Brunsdon, COO of Screen Australia, highlighted the toolkit's role in promoting confidence and clarity in screen project investments, ultimately supporting a robust, inclusive industry and talent development.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop